Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 65.20% from the company’s previous close. HC Wainwright also issued estimates for Theravance Biopharma’s FY2028 earnings at $1.11 EPS and FY2029 earnings at $3.87 EPS.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $9.08 on Tuesday. The firm’s 50-day moving average is $9.35 and its 200-day moving average is $8.91. The company has a market cap of $446.50 million, a price-to-earnings ratio of -8.99 and a beta of 0.21. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Equities analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aquatic Capital Management LLC bought a new stake in Theravance Biopharma in the fourth quarter valued at about $25,000. Quantbot Technologies LP acquired a new stake in Theravance Biopharma during the third quarter valued at approximately $60,000. KLP Kapitalforvaltning AS bought a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $69,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,696 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the 4th quarter worth approximately $103,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.